Royal Hallamshire Hospital

Running trials

• Recruiting

  A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

  NCT07830732· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

  NCT07285655· Phase 3· Liquidia Technologies, Inc.· Source

• Recruiting

  Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

  NCT07287397· Phase 1/2· Vector Y Therapeutics· Source

• Active, not recruiting

  Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  NCT07087054· Phase 3· Crinetics Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

  NCT07206225· Phase 1· Pfizer· Source

• Recruiting

  A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

  NCT07220564· Phase 1· Novo Nordisk A/S· Source

• Recruiting

  Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

  NCT07139743· Phase 1· Autolus Limited· Source

• Recruiting

  A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial

  NCT06786234· Phase 2· Step Pharma, SAS· Source

• Enrolling by invitation

  A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

  NCT06926621· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Remote Ischaemic Conditioning for Fatigue After Stroke 2 (RICFAST 2)

  NCT07914647· Phase 2· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Recruiting

  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

  NCT06609226· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

  NCT06619860· Phase 2· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source

• Recruiting

  A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

  NCT06297590· Phase 1· Eli Lilly and Company· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Active, not recruiting

  A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

  NCT06185764· Phase 1/2· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

  NCT05685238· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study Evaluating the Safety and Tolerability of QRL-201 in ALS

  NCT05633459· Phase 1· QurAlis Corporation· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Biogen· Source

• Recruiting

  Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  NCT05429632· Phase 3· Priothera SAS· Source

• Recruiting

  Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

  NCT04685616· Phase 3· University College, London· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

  NCT05201638· Phase 3· Immunic AG· Source

• Active, not recruiting

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

  NCT07218029· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Methods of T Cell Depletion Trial (MoTD)

  NCT04888741· Phase 2· University of Birmingham· Source

• Active, not recruiting

  A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

  NCT04624659· Phase 3· Forma Therapeutics, Inc.· Source

• Recruiting

  A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

  NCT04307576· Phase 3· Mats Heyman· Source

• Active, not recruiting

  Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

  NCT04082429· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

  NCT04116502· Phase 3· University of Birmingham· Source

• Active, not recruiting

  Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

  NCT04083781· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

  NCT03899337· Phase 2· University of Birmingham· Source

• Enrolling by invitation

  A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

  NCT03745924· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT03462719· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

  NCT03165734· Phase 3· Swedish Orphan Biovitrum· Source

• Recruiting

  The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  NCT03562169· Phase 3· University of Leeds· Source

• Active, not recruiting

  Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma

  NCT02315716· Phase 2· University College, London· Source

• Active, not recruiting

  Prostate Testing for Cancer and Treatment

  NCT02044172· University of Oxford· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers3 recruiting
• Haemophilia3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• High blood pressure2 recruiting
• Hodgkin lymphoma2 recruiting
• Multiple myeloma2 recruiting
• Pulmonary arterial hypertension2 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Bladder cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Diabetic neuropathy1 recruiting
• Frontotemporal dementia1 recruiting
• Mild cognitive impairment1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myotonic dystrophy1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting

Closed trials

• Completed

  A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

  NCT06797869· Phase 2· Novo Nordisk A/S· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  Traditional Dietary Advice Vs. Mediterranean Diet in IBS

  NCT05985018· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Completed

  A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

  NCT05878938· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

  NCT05353985· Phase 2· Takeda· Source

• Completed

  Verapamil SR in Adults With Type 1 Diabetes

  NCT04545151· Phase 2· Medical University of Graz· Source

• Completed

  Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT

  NCT04173533· Phase 3· University of Birmingham· Source

• Completed

  A Trial of the May Health Device in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With PCOS Infertility

  NCT03760926· May Health· Source

• Completed

  Remote Ischaemic Conditioning for Fatigue After Stroke

  NCT03794947· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Hoffmann-La Roche· Source

• Completed

  Multiple Sclerosis-Simvastatin Trial 2

  NCT03387670· Phase 3· University College, London· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

  NCT03126019· Phase 2· Incyte Corporation· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· LivaNova· Source

• Completed

  Differences in Preparation for Small Bowel Capsule Endoscopy

  NCT03351972· Phase 4· Sheffield Teaching Hospitals NHS Foundation Trust· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Incyte Corporation· Source

• Completed

  Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

  NCT02699645· Phase 3· The George Institute· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· University College Dublin· Source

• Recruiting

  @neurIST : Intregrated Biomedical Informatics for the Management of Cerebral Aneurysms

  NCT05526352· University Hospital, Geneva· Source

• Completed

  Stereotactic Radiotherapy for Wet AMD (STAR)

  NCT02243878· Phase 3· King's College Hospital NHS Trust· Source

• Completed

  A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

  NCT00676715· Phase 2· Genentech, Inc.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Pulmonary arterial hypertension13 works · 4 trials
• Coeliac disease9 works · 2 trials